Loading clinical trials...
Loading clinical trials...
Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.
Age
0 - 120 years
Sex
ALL
Healthy Volunteers
No
Aichi Medical University Hosp /ID# 152220
Nagakute, Aichi-ken, Japan
Nagoya City University Hospital /ID# 153642
Nagoya, Aichi-ken, Japan
Japanese Red Cross Narita Hosp /ID# 155894
Narita-shi, Chiba, Japan
Kikkoman General Hospital /ID# 152139
Noda, Chiba, Japan
Matsuyama Red Cross Hosp /ID# 152271
Matsuyama, Ehime, Japan
NHO Kyushu Medical Center /ID# 153001
Fukuoka, Fukuoka, Japan
Fukuoka University Hospital /ID# 152272
Fukuoka, Fukuoka, Japan
Kurume University Hospital /ID# 152099
Kurume-shi, Fukuoka, Japan
Gifu University Hospital /ID# 152993
Gifu, Gifu, Japan
Kusunoki Hospital /ID# 152072
Fujioka, Gunma, Japan
Start Date
January 5, 2016
Primary Completion Date
February 28, 2019
Completion Date
February 28, 2019
Last Updated
February 24, 2020
3,043
ACTUAL participants
Lead Sponsor
AbbVie
NCT02219490
NCT02167945
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02707952